Reputation and precedent in the bevacizumab decision

N Engl J Med. 2011 Jul 14;365(2):e3. doi: 10.1056/NEJMp1107201. Epub 2011 Jun 27.

Authors

Daniel Carpenter¹, Aaron S Kesselheim, Steven Joffe

Affiliation

¹ Department of Government, Harvard University, Cambridge, MA, USA.

PMID: 21707383
DOI: 10.1056/NEJMp1107201

No abstract available

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Breast Neoplasms / drug therapy*
Breast Neoplasms / mortality
Breast Neoplasms / pathology
Disease-Free Survival
Drug Approval*
Drug Industry / legislation & jurisprudence*
Female
Humans
Neoplasm Metastasis
United States
United States Food and Drug Administration

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab